Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
Trastuzumab has recently been introduced as a treatment for HER2-positive metastatic and/or unresectable gastric cancer (MUGC); however, compared with breast cancer, some issues concerning HER2 and trastuzumab therapy for gastric cancer remain unclear. A 74-year-old woman received trastuzumab-contai...
Tallennettuna:
| Päätekijät: | , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Wiley
2015-01-01
|
| Sarja: | Case Reports in Gastrointestinal Medicine |
| Linkit: | http://dx.doi.org/10.1155/2015/132030 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|